RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Harbour BioMed formed a strategic collaboration with Philadelphia’s Wistar Institute to co-discover novel antibodies for cancer and infectious disease indications. The agreement combines Harbour BioMed’s drug discovery platform with Wistar’s research in cancer and infectious disease biology, aiming to generate fully human monoclonal antibodies for novel targets. Headquartered in Cambridge, Mass., Harbour has an R&D operation in Shanghai and a drug discovery platform in Rotterdam. Financial details of the multi-year, multifaceted research program were not disclosed.
Source: China Biotoday
